Patient characteristics and outcomes associated with nitrovasodilator use in the treatment of acute heart failure

Peter Pang, Amir Goren, Lewis Kopenhafer, Jinhee Park

Research output: Contribution to journalArticle

Abstract

Nitrovasodilators (NVs) are commonly recommended for the treatment of acute heart failure (AHF); however, registries suggest their use is not common. The objectives of this study were to determine patient characteristics associated with NV use and to explore the association between NV use and outcomes [length of stay (LoS) and inpatient mortality] in patients with AHF. A survey of US physicians (n 426) who treat at least 5 AHF patients per month with NV provided a patient sample (n 812 treated with NV and n 322 not-NV) derived from chart review. Factors associated with NV use as well as patient characteristics and outcomes associated with NV use were explored using bivariate analysis, logistic regression, and negative binomial regression as appropriate. NV-treated patients were more likely to be female, have a higher systolic blood pressure, higher B-type natriuretic peptide and troponin, and stay in the intensive care unit while hospitalized, but less likely to be hyponatremic or hospitalized once previously. Overall, average LoS was 5.10 days (SD 4.52) with 5.21 days (SD 0.15) for the NV group and 4.94 days (SD 0.31) for the non-NV group. The overall inpatient mortality rate was 2.1%. Among physicians who frequently use NV to treat AHF patients, there are distinct patient characteristics between NV treated and nontreated patients, suggesting a phenotype-driven approach. However, no differences in LoS or mortality were observed.

Original languageEnglish
Pages (from-to)206-213
Number of pages8
JournalAmerican Journal of Therapeutics
Volume22
Issue number3
DOIs
StatePublished - May 16 2015

Fingerprint

Heart Failure
Length of Stay
Therapeutics
Mortality
Inpatients
Physicians
Troponin
Brain Natriuretic Peptide
Intensive Care Units
Registries
Logistic Models
Blood Pressure
Hypertension
Phenotype

Keywords

  • acute heart failure
  • emergency room
  • nitrates
  • vasodilator

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Patient characteristics and outcomes associated with nitrovasodilator use in the treatment of acute heart failure. / Pang, Peter; Goren, Amir; Kopenhafer, Lewis; Park, Jinhee.

In: American Journal of Therapeutics, Vol. 22, No. 3, 16.05.2015, p. 206-213.

Research output: Contribution to journalArticle

@article{0af62641fbe349f684ee097b719fe2fe,
title = "Patient characteristics and outcomes associated with nitrovasodilator use in the treatment of acute heart failure",
abstract = "Nitrovasodilators (NVs) are commonly recommended for the treatment of acute heart failure (AHF); however, registries suggest their use is not common. The objectives of this study were to determine patient characteristics associated with NV use and to explore the association between NV use and outcomes [length of stay (LoS) and inpatient mortality] in patients with AHF. A survey of US physicians (n 426) who treat at least 5 AHF patients per month with NV provided a patient sample (n 812 treated with NV and n 322 not-NV) derived from chart review. Factors associated with NV use as well as patient characteristics and outcomes associated with NV use were explored using bivariate analysis, logistic regression, and negative binomial regression as appropriate. NV-treated patients were more likely to be female, have a higher systolic blood pressure, higher B-type natriuretic peptide and troponin, and stay in the intensive care unit while hospitalized, but less likely to be hyponatremic or hospitalized once previously. Overall, average LoS was 5.10 days (SD 4.52) with 5.21 days (SD 0.15) for the NV group and 4.94 days (SD 0.31) for the non-NV group. The overall inpatient mortality rate was 2.1{\%}. Among physicians who frequently use NV to treat AHF patients, there are distinct patient characteristics between NV treated and nontreated patients, suggesting a phenotype-driven approach. However, no differences in LoS or mortality were observed.",
keywords = "acute heart failure, emergency room, nitrates, vasodilator",
author = "Peter Pang and Amir Goren and Lewis Kopenhafer and Jinhee Park",
year = "2015",
month = "5",
day = "16",
doi = "10.1097/MJT.0000000000000211",
language = "English",
volume = "22",
pages = "206--213",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Patient characteristics and outcomes associated with nitrovasodilator use in the treatment of acute heart failure

AU - Pang, Peter

AU - Goren, Amir

AU - Kopenhafer, Lewis

AU - Park, Jinhee

PY - 2015/5/16

Y1 - 2015/5/16

N2 - Nitrovasodilators (NVs) are commonly recommended for the treatment of acute heart failure (AHF); however, registries suggest their use is not common. The objectives of this study were to determine patient characteristics associated with NV use and to explore the association between NV use and outcomes [length of stay (LoS) and inpatient mortality] in patients with AHF. A survey of US physicians (n 426) who treat at least 5 AHF patients per month with NV provided a patient sample (n 812 treated with NV and n 322 not-NV) derived from chart review. Factors associated with NV use as well as patient characteristics and outcomes associated with NV use were explored using bivariate analysis, logistic regression, and negative binomial regression as appropriate. NV-treated patients were more likely to be female, have a higher systolic blood pressure, higher B-type natriuretic peptide and troponin, and stay in the intensive care unit while hospitalized, but less likely to be hyponatremic or hospitalized once previously. Overall, average LoS was 5.10 days (SD 4.52) with 5.21 days (SD 0.15) for the NV group and 4.94 days (SD 0.31) for the non-NV group. The overall inpatient mortality rate was 2.1%. Among physicians who frequently use NV to treat AHF patients, there are distinct patient characteristics between NV treated and nontreated patients, suggesting a phenotype-driven approach. However, no differences in LoS or mortality were observed.

AB - Nitrovasodilators (NVs) are commonly recommended for the treatment of acute heart failure (AHF); however, registries suggest their use is not common. The objectives of this study were to determine patient characteristics associated with NV use and to explore the association between NV use and outcomes [length of stay (LoS) and inpatient mortality] in patients with AHF. A survey of US physicians (n 426) who treat at least 5 AHF patients per month with NV provided a patient sample (n 812 treated with NV and n 322 not-NV) derived from chart review. Factors associated with NV use as well as patient characteristics and outcomes associated with NV use were explored using bivariate analysis, logistic regression, and negative binomial regression as appropriate. NV-treated patients were more likely to be female, have a higher systolic blood pressure, higher B-type natriuretic peptide and troponin, and stay in the intensive care unit while hospitalized, but less likely to be hyponatremic or hospitalized once previously. Overall, average LoS was 5.10 days (SD 4.52) with 5.21 days (SD 0.15) for the NV group and 4.94 days (SD 0.31) for the non-NV group. The overall inpatient mortality rate was 2.1%. Among physicians who frequently use NV to treat AHF patients, there are distinct patient characteristics between NV treated and nontreated patients, suggesting a phenotype-driven approach. However, no differences in LoS or mortality were observed.

KW - acute heart failure

KW - emergency room

KW - nitrates

KW - vasodilator

UR - http://www.scopus.com/inward/record.url?scp=84929509701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929509701&partnerID=8YFLogxK

U2 - 10.1097/MJT.0000000000000211

DO - 10.1097/MJT.0000000000000211

M3 - Article

VL - 22

SP - 206

EP - 213

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 3

ER -